Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Intercept Pharmaceuticals (NQ: ICPT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 18.92 (39)
Ask (Size) 19.02 (1,075)
Prev. Close 19.00
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 41,782,727
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800... 
Via Benzinga
Top 5 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga

Performance

More News

Read More
Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now
Via InvestorPlace
INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT
From Kahn Swick & Foti, LLC
Via Business Wire
Analyst Expectations for Intercept Pharma's Future
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
Why Intercept Pharmaceuticals Stock Is Skyrocketing Today
Via The Motley Fool
Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) is a Leading Gainer in Tuesday Morning Trading
Via Investor Brand Network
Dow Tumbles 150 Points; US House Prices Rise in July
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Rare Liver Disease Focused Intercept Pharmaceuticals Stock Trading Higher Today?
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
ICPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Via Benzinga
Why CymaBay Therapeutics Stock Is Jumping Today
Via The Motley Fool
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.